MX2015006986A - Solucion de trombina y metodos de uso de esta. - Google Patents

Solucion de trombina y metodos de uso de esta.

Info

Publication number
MX2015006986A
MX2015006986A MX2015006986A MX2015006986A MX2015006986A MX 2015006986 A MX2015006986 A MX 2015006986A MX 2015006986 A MX2015006986 A MX 2015006986A MX 2015006986 A MX2015006986 A MX 2015006986A MX 2015006986 A MX2015006986 A MX 2015006986A
Authority
MX
Mexico
Prior art keywords
methods
thrombin solution
thrombin
lyophilization
solution
Prior art date
Application number
MX2015006986A
Other languages
English (en)
Other versions
MX358132B (es
Inventor
Liliana Bar
Israel Nur
Roberto Meidler
Oleg Belyaev
Original Assignee
Omrix Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omrix Biopharmaceuticals Ltd filed Critical Omrix Biopharmaceuticals Ltd
Publication of MX2015006986A publication Critical patent/MX2015006986A/es
Publication of MX358132B publication Critical patent/MX358132B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Se proporcionan métodos para la liofilización de una solución acuosa de trombina, soluciones de trombina para usar en dichos métodos de liofilización, y composiciones sólidas de trombina producidas mediante dichos métodos.
MX2015006986A 2012-12-03 2013-11-28 Solucion de trombina y metodos de uso de esta. MX358132B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL22339612 2012-12-03
US201361753542P 2013-01-17 2013-01-17
PCT/IL2013/000088 WO2014087394A1 (en) 2012-12-03 2013-11-28 Thrombin solution and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2015006986A true MX2015006986A (es) 2015-09-23
MX358132B MX358132B (es) 2018-08-06

Family

ID=50825810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006986A MX358132B (es) 2012-12-03 2013-11-28 Solucion de trombina y metodos de uso de esta.

Country Status (14)

Country Link
US (4) US9212357B2 (es)
EP (2) EP3760221A1 (es)
JP (2) JP6526565B2 (es)
KR (1) KR102101611B1 (es)
CN (2) CN110251468A (es)
AU (1) AU2013353636B2 (es)
BR (2) BR122022012099B1 (es)
CA (1) CA2892083A1 (es)
HK (1) HK1214958A1 (es)
IL (1) IL239043B (es)
MX (1) MX358132B (es)
PL (1) PL2925347T3 (es)
RU (1) RU2670956C9 (es)
WO (1) WO2014087394A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
TW201702385A (zh) * 2015-03-13 2017-01-16 崇謹 孫 穩定凝血酶之方法及其組合物
US10159720B2 (en) 2015-12-08 2018-12-25 Omrix Biopharmaceuticals Ltd Thrombin microcapsules, preparation and uses thereof
IL242984A0 (en) * 2015-12-08 2016-02-29 Omrix Biopharmaceuticals Ltd Thrombin microcapsules, their preparation and how to use them
US10420134B2 (en) 2016-02-02 2019-09-17 Cisco Technology, Inc. System and method to facilitate subframe scheduling in a split medium access control radio access network environment
CN109010906B (zh) * 2018-08-16 2021-05-14 陈明远 一种促进术后伤口局部止血及促进术后创面上皮化的生物胶水及其工作方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JP2715104B2 (ja) * 1988-08-18 1998-02-18 株式会社ミドリ十字 トロンビン乾燥製剤
DE3843126C3 (de) 1988-12-22 1994-10-06 Octapharma Ag Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates
KR100303872B1 (ko) 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
CN1100655A (zh) * 1992-11-19 1995-03-29 迟斌元 一种含有缓冲剂和凝血酶的药物组合物
JP3028274B2 (ja) * 1994-09-30 2000-04-04 持田製薬株式会社 トロンビン固形製剤の安定化方法
GB9503750D0 (en) 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US20060127460A1 (en) * 2002-11-14 2006-06-15 Juridical Foundation The Chemosero-Therapeutic Research Institute Trombin-carrying bioabsorbable synthetic nonwoven fabric
EP1927658B1 (en) 2004-06-22 2012-10-10 Zymogenetics, Inc. Thrombin compositions
JP4767253B2 (ja) 2004-06-22 2011-09-07 ザイモジェネティクス， インコーポレイテッド トロンビン組成物
ES2226587B1 (es) * 2004-10-22 2005-12-16 Probitas Pharma, S.A. Composicion de trombina estable.
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
CN101282908A (zh) * 2005-09-05 2008-10-08 兰贝克赛实验室有限公司 制备冻干的碳酸氢钠的方法
BRPI0717674A2 (pt) 2006-11-24 2014-04-08 Cadila Healthcare Ltd ' formulação compreendendo conjugados de peg-interferon alfa, processo de liofilização da formulação e formulação liofilizada '
AU2007334394B2 (en) * 2006-12-15 2013-06-06 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants
CN101214374A (zh) * 2007-01-05 2008-07-09 兆科药业（合肥）有限公司 具有促凝血与止血功能的制剂
KR101541702B1 (ko) * 2008-03-03 2015-08-04 옴릭스 바이오파머슈티컬스 리미티드 활성 성분을 포함하는 젤라틴 스펀지, 이의 제조 방법 및 용도
US10039865B2 (en) * 2008-09-22 2018-08-07 Omrix Biopharmaceuticals Ltd. Implantable device comprising a substrate pre-coated with stabilized fibrin
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
DK2947148T3 (en) 2010-04-20 2017-09-18 Octapharma Ag NEW STABILIZER FOR PHARMACEUTICAL PROTEINS
CA2801120C (en) * 2010-06-01 2019-08-20 Baxter International Inc. Process for making dry and stable hemostatic compositions
IL207586A0 (en) 2010-08-12 2010-12-30 Omrix Biopharmaceuticals Ltd A fibrin based therapeutic preparation and use thereof
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof

Also Published As

Publication number Publication date
RU2670956C9 (ru) 2018-11-21
CN110251468A (zh) 2019-09-20
IL239043A0 (en) 2015-07-30
PL2925347T3 (pl) 2020-12-28
MX358132B (es) 2018-08-06
US10479987B2 (en) 2019-11-19
JP6526565B2 (ja) 2019-06-05
CA2892083A1 (en) 2014-06-12
BR112015013071B1 (pt) 2023-01-17
US20200032239A1 (en) 2020-01-30
KR20150091503A (ko) 2015-08-11
RU2670956C2 (ru) 2018-10-26
US20220098570A1 (en) 2022-03-31
AU2013353636A1 (en) 2015-07-16
AU2013353636B2 (en) 2018-03-01
EP2925347A1 (en) 2015-10-07
JP2016505543A (ja) 2016-02-25
US20160060614A1 (en) 2016-03-03
US20140154773A1 (en) 2014-06-05
IL239043B (en) 2020-09-30
US11993797B2 (en) 2024-05-28
JP2018162254A (ja) 2018-10-18
BR122022012099B1 (pt) 2023-01-24
US9212357B2 (en) 2015-12-15
KR102101611B1 (ko) 2020-04-20
EP2925347B1 (en) 2020-08-26
US11225652B2 (en) 2022-01-18
BR112015013071A2 (pt) 2017-07-11
EP3760221A1 (en) 2021-01-06
HK1214958A1 (zh) 2016-08-12
CN104822387A (zh) 2015-08-05
RU2015126540A (ru) 2017-01-13
WO2014087394A1 (en) 2014-06-12
BR112015013071A8 (pt) 2019-10-08

Similar Documents

Publication Publication Date Title
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
PH12014502602A1 (en) Methods for improving safety of blood-brain barrier transport
MX2019008212A (es) Estructuras fibrosas que comprenden particulas y metodos para fabricarlas.
MX2020002544A (es) Sales de glicopirrolato.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
IN2014DN08481A (es)
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
MY169141A (en) Biodegradable compositions, methods and uses thereof
MX359769B (es) Metodos para descelularizar huesos.
MY168166A (en) Polymer and Composition Including Same, and Adhesive Composition
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
IN2014DN06104A (es)
CA2905610C (en) Hyaluronic acid derivatives
MY161601A (en) Films and compositions comprising the same
MX358132B (es) Solucion de trombina y metodos de uso de esta.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
WO2013163297A8 (en) Modified glycoproteins
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
RU2012151073A (ru) Способ стабилизации раствора дигидрокверцетина
MX2015016603A (es) Composiciones de corticosteroides.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
UY34564A (es) Utilización en terapéutica de derivados de imidazopiridina
NZ708737A (en) Thrombin solution and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration